SOCMA Issues Statement to US Senate Subcommittee on TSCA Reform - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SOCMA Issues Statement to US Senate Subcommittee on TSCA Reform

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Society of Chemical Manufacturers and Affiliates (SOCMA), in a statement submitted to the US Senate Subcommittee on Superfund, Toxic and Environmental Health, provided support for a bipartisan review of the Toxic Substances Control Act (TSCA) as that subcommittee considers reforming the  chemical-control law. SOCMA is a trade association representing custom and batch manufacturers, including contract manufacturers of active pharmaceutical ingredients, pharmaceutical intermediates, and other fine and specialty chemicals.

“SOCMA understands that TSCA modernization is a complex issue that deserves close scrutiny,” said SOCMA President Lawrence D. Sloan in a SOCMA Feb. 3, 2011, press release. “Many relevant factors should be considered, most of which, we believe, fall outside the statute itself.”

Sloan said that TSCA's critics selectively cite chemical statistics that paint an incomplete picture of TSCA’s effectiveness. He underscored the fact that these statistics alone make it appear as if TSCA has failed due to a relatively low number of restricted chemicals, but contended that a great deal of testing is conducted. He added that most chemicals can be used safely and therefore do not require additional restrictions. Sloan noted that there are many other federal laws that govern chemicals management and that advances in the field of analytical chemistry should be acknowledged before “placing  blame solely on TSCA for increased exposures,” according to the SOCMA release.

SOCMA asked the subcommittee to consider various metrics to evaluate TSCA before introducing new legislation, such as the following:

  • The number of new chemicals reviewed by the Environmental Protection Agency under Section 5 since TSCA’s inception
  • The number of Pre-Manufacturing Notices (PMN) that were withdrawn as a result of those reviews
  • The number of PMNs for which review periods were voluntarily suspended while the submitter conducted tests or gathered other data
  • The number of Significant New Use Rules (SNURs) issued by EPA
  • The number of existing chemicals actually in commerce.

“Ultimately, success will not depend solely or primarily on how many chemicals are restricted, but on the net health, environmental, and economic effects of implementing these laws,” Sloan said in the release.

SOCMA said it will continue its efforts to promote recommendations for a “pragmatic approach” to TSCA modernization with members of Congress. On Apr. 13, 2011, SOCMA members will discuss their position with lawmakers and their staff during the association’s annual Washington Fly-In.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here